首页 | 本学科首页   官方微博 | 高级检索  
检索        

丁苯酞软胶囊治疗进展性卒中的系统评价
引用本文:卢柳,谢娟,郭书英.丁苯酞软胶囊治疗进展性卒中的系统评价[J].中国现代应用药学,2020,37(9):1121-1128.
作者姓名:卢柳  谢娟  郭书英
作者单位:川北医学院第二临床医学院/南充市中心医院老年病科, 四川 南充 637000;河北医科大学第二附属医院神经内科, 石家庄 050000
基金项目:四川省卫生健康委员会科研课题(19PJ058)
摘    要:目的系统评价丁苯酞软胶囊治疗进展性卒中的疗效和安全性。方法检索Cochrane图书馆、万方、CNKI等数据库收集关于丁苯酞治疗进展性卒中的随机对照试验(randomized controlled trials,RCTs),时间截至2018年12月,根据明确的纳入与排除标准筛选相关研究,采用RevMan 5.3软件进行统计分析。结果共纳入26个RCTs(2519例患者),meta分析结果示,与对照组比较,丁苯酞治疗进展性卒中疗效更好(RR=1.23,95%CI 1.17~1.29,P<0.00001);丁苯酞治疗进展性卒中在神经功能缺损评分(The National Institutes of Health Stroke Scale,NIHSS)(MD=-3.01,95%CI-3.49^-2.52,P<0.00001)、卒中评分量表(Chinese Stroke Scale,CSS)评分(MD=-3.39,95%CI-4.70^-2.08,P<0.00001)及日常生活活动能力评分量表(Barthel Index,BI)评分(MD=9.84,95%CI 6.06~13.62,P<0.00001)改善方面均优于对照组,差异有统计学意义。2组在不良反应方面差异无统计学意义(RR=1.27,95%CI 0.50~3.18,P=0.61)。结论丁苯酞软胶囊能有效改善进展性卒中患者的神经功能,且不增加不良反应。

关 键 词:进展性卒中  丁苯酞  系统评价  META分析
收稿时间:2019/5/8 0:00:00
修稿时间:2020/4/13 0:00:00

Butylphthalide Soft Capsule for the Treatment of Progressive Stroke: A Systematic Review
LU Liu,XIE Juan,GUO Shuying.Butylphthalide Soft Capsule for the Treatment of Progressive Stroke: A Systematic Review[J].The Chinese Journal of Modern Applied Pharmacy,2020,37(9):1121-1128.
Authors:LU Liu  XIE Juan  GUO Shuying
Institution:Department of Geriatrics, The Second Clinical School of North Sichuan Medical College/Nanchong Central Hospital, Nanchong 637000, China; Department of Neurology, The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang 050000, China
Abstract:OBJECTIVE To systematically assess the clinical efficacy and safety of butylphthalide soft capsule for patients with progressive stroke.METHODS Databases including Cochrane library,Wan Fang data and CNKI and so on were searched to collect randomized controlled trials(RCTs)about butylphthalide for patients with progressive stroke from inception to December 2018.Two reviewers independently screened the literature,extracted data and assessed the risk of bias of the included studies.Then,RevMan 5.3 software was used to perform meta-analysis.RESULTS Twenty-six RCTs involving 2519 patients were included.Results of meta-analysis showed that the butylphthalide group were superior to those of the control group in the clinical efficacy rate(RR=1.23,95%CI 1.17-1.29,P<0.00001),The National Institutes of Health Stroke Scale score(MD=-3.0195%CI-3.49--2.52,P<0.00001),Chinese Stroke Scale score(MD=-3.39,95%CI-4.70--2.08,P<0.00001)and Barthel Index score(MD=9.84,95%CI 6.06-13.62,P<0.00001),and these differences were statistically significant,while there was no statistical difference between the two groups in the incidence of adverse events(RR=1.27,95%CI 0.50-3.18,P=0.61).CONCLUSION Butylphthalide soft capsule can improve the neurological function for patients with progressive stroke without increasing the incidents of adverse events.
Keywords:progressive stroke  butylphthalide  systematic review  meta-analysis
本文献已被 维普 等数据库收录!
点击此处可从《中国现代应用药学》浏览原始摘要信息
点击此处可从《中国现代应用药学》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号